|
US6465488B1
(en)
|
1997-12-11 |
2002-10-15 |
Chancellor, Masters & Scholars Of The University Of Oxford |
Inhibition of glycolipid biosynthesis
|
|
US6274597B1
(en)
*
|
1998-06-01 |
2001-08-14 |
Mount Sinai School Of Medicine Of New York University |
Method of enhancing lysosomal α-Galactosidase A
|
|
US6610703B1
(en)
|
1998-12-10 |
2003-08-26 |
G.D. Searle & Co. |
Method for treatment of glycolipid storage diseases
|
|
GB9909064D0
(en)
*
|
1999-04-20 |
1999-06-16 |
Oxford Glycosciences Uk Ltd |
Therapies
|
|
GB0100889D0
(en)
|
2001-01-12 |
2001-02-21 |
Oxford Glycosciences Uk Ltd |
Compounds
|
|
WO2000066105A2
(en)
*
|
1999-04-30 |
2000-11-09 |
The Trustees Of Boston College |
Treatment of epilepsy with imino sugars
|
|
JP2003505430A
(ja)
|
1999-07-26 |
2003-02-12 |
ジー・ディー・サール・アンド・カンパニー |
デオキシノジリマイシンの長鎖ｎ−アルキル誘導体およびグルコセレブロシダーゼ酵素の糖脂質異常蓄積疾患の治療用の薬剤の製造のための使用
|
|
US6770468B1
(en)
|
1999-09-14 |
2004-08-03 |
Genzyme Glycobiology Research Institute, Inc. |
Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway
|
|
US6534300B1
(en)
|
1999-09-14 |
2003-03-18 |
Genzyme Glycobiology Research Institute, Inc. |
Methods for producing highly phosphorylated lysosomal hydrolases
|
|
US7560424B2
(en)
|
2001-04-30 |
2009-07-14 |
Zystor Therapeutics, Inc. |
Targeted therapeutic proteins
|
|
EP1436316B1
(en)
*
|
2001-04-30 |
2008-01-23 |
ZyStor Therapeutics , Inc. |
Subcellular targeting of therapeutic proteins
|
|
US20040005309A1
(en)
*
|
2002-05-29 |
2004-01-08 |
Symbiontics, Inc. |
Targeted therapeutic proteins
|
|
US7629309B2
(en)
*
|
2002-05-29 |
2009-12-08 |
Zystor Therapeutics, Inc. |
Targeted therapeutic proteins
|
|
US20030072761A1
(en)
*
|
2001-10-16 |
2003-04-17 |
Lebowitz Jonathan |
Methods and compositions for targeting proteins across the blood brain barrier
|
|
US6800472B2
(en)
|
2001-12-21 |
2004-10-05 |
Genzyme Glycobiology Research Institute, Inc. |
Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
|
|
US6905856B2
(en)
|
2001-12-21 |
2005-06-14 |
Genzyme Glycobiology Research Institute, Inc. |
Soluble GlcNAc phosphotransferase
|
|
US20030124652A1
(en)
*
|
2001-12-21 |
2003-07-03 |
Novazyme Pharmaceuticals, Inc. |
Methods of producing high mannose glycoproteins in complex carbohydrate deficient cells
|
|
AU2003248960B2
(en)
*
|
2002-07-17 |
2009-06-25 |
Idorsia Pharmaceuticals Ltd |
Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase
|
|
ES2393331T3
(es)
*
|
2002-07-17 |
2012-12-20 |
Actelion Pharmaceuticals Ltd. |
Derivados de piperidintriol como inhibidores de la glucosiliceramida sintasa
|
|
AU2003302724A1
(en)
*
|
2002-08-13 |
2004-07-09 |
Mcivor, Scott, R. |
Methods of using vectors to treat metabolic disorders
|
|
JP5589165B2
(ja)
*
|
2003-01-31 |
2014-09-17 |
マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー |
タンパク質欠損性障害の治療のための併用療法
|
|
GB0313677D0
(en)
*
|
2003-06-13 |
2003-07-16 |
Oxford Glycosciences Uk Ltd |
Novel compound
|
|
GB0313678D0
(en)
*
|
2003-06-13 |
2003-07-16 |
Oxford Glycosciences Uk Ltd |
Novel compounds
|
|
DE602005020745D1
(de)
*
|
2004-02-10 |
2010-06-02 |
Zystor Therapeutics Inc |
Saure alpha-glukosidase und fragmente davon
|
|
US20050208090A1
(en)
*
|
2004-03-18 |
2005-09-22 |
Medtronic, Inc. |
Methods and systems for treatment of neurological diseases of the central nervous system
|
|
DE102004029310A1
(de)
*
|
2004-06-17 |
2005-12-29 |
Clariant Gmbh |
Hochkonzentrierte, wässrige Formulierungen von Oligo-und Polyestern
|
|
EP1773401B1
(en)
*
|
2004-06-21 |
2013-01-02 |
Medtronic, Inc. |
Medical systems and methods for delivering compositions to cells
|
|
WO2006037069A1
(en)
*
|
2004-09-28 |
2006-04-06 |
Allergan, Inc. |
Compositions comprising nb-dnj, ne-dnj or d-glucaro-delta-lactam and their uses for the treatment of pain and other neurological conditions
|
|
US8500720B2
(en)
*
|
2005-05-09 |
2013-08-06 |
Medtronic, Inc |
Method and apparatus for treatment of cardiac disorders
|
|
EP3782655A1
(en)
|
2005-05-17 |
2021-02-24 |
Amicus Therapeutics, Inc. |
A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
|
|
AU2007322123A1
(en)
*
|
2006-11-13 |
2008-05-29 |
Biomarin Pharmaceutical Inc. |
Methods for treating Pompe disease
|
|
US8419710B2
(en)
*
|
2006-12-06 |
2013-04-16 |
Medtronic, Inc. |
Methods for infusing fluids via an implantable infusion system
|
|
WO2009137721A2
(en)
|
2008-05-07 |
2009-11-12 |
Zystor Therapeutics, Inc. |
Lysosomal targeting peptides and uses thereof
|
|
WO2010056746A1
(en)
*
|
2008-11-11 |
2010-05-20 |
Amicus Therapeutics, Inc. |
Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease
|
|
US8785168B2
(en)
|
2009-06-17 |
2014-07-22 |
Biomarin Pharmaceutical Inc. |
Formulations for lysosomal enzymes
|
|
US20110195985A1
(en)
*
|
2010-02-09 |
2011-08-11 |
The Hospital For Sick Children |
Compounds for the treatment of lysosomal storage diseases
|
|
EP3318277A1
(en)
*
|
2016-11-04 |
2018-05-09 |
Institut du Cerveau et de la Moelle Epiniere-ICM |
Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
|